Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Public ClinicalTrials.gov record NCT01844765. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Open Label, Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib
Study identification
- NCT ID
- NCT01844765
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 59 participants
Conditions and interventions
Interventions
- nilotinib Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 19, 2013
- Primary completion
- May 31, 2016
- Completion
- Aug 27, 2020
- Last update posted
- Apr 21, 2021
2013 – 2020
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Loma Linda University Cancer Center | Loma Linda | California | 92350 | — |
| Lucile Salter Packard Children's Hospital at Stanford | Palo Alto | California | 94304 | — |
| Nemours Childrens Hospital | Orlando | Florida | 32827 | — |
| St. Mary's Hospital | West Palm Beach | Florida | 33407 | — |
| Johns Hopkins Oncology Center ORA | Baltimore | Maryland | 21231 | — |
| UNC Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Nationwide Childrens Hospital | Columbus | Ohio | 43205 | — |
| University of Texas Southwestern Medical Center Oncology | Dallas | Texas | 75235 | — |
| Cook Children's Medical Center Oncology | Fort Worth | Texas | 76104 | — |
| Seattle Childrens Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01844765, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2021 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01844765 live on ClinicalTrials.gov.